

OCT and OCT Angiography Something Old and Something New Retina Pearls

Greg Caldwell, OD, FAAO

Nashville – Music City Fall Classic 2022 Optometric Education Consultants

Saturday, October 22, 2022



Disclosures- Greg Caldwell, OD, FAAO

All relevant relationships have been mitigated

- •• The content of this activity was prepared independently by me Dr. Caldwell
- •• Lectured for: Alcon, Allergan, Aerie, BioTissue, Kala, Maculogix, Optovue, RVL, Heru
 - Disclosure: Receive speaker honorariums
- Advisory Board: Allergan, Sun, Alcon, Maculogix, Dompe, Visus, Eyenovia
 - Disclosure: Receive participant honorariums
- •• I have no direct financial or proprietary interest in any companies, products or services mentioned in this presentation
 - Disclosure: Non-salaried financial affiliation with Pharmanex
- •• Envolve: PA Medical Director, Credential Committee
- Healthcare Registries Chairman of Advisory Council for Diabetes
- •• The content and format of this course is presented without commercial bias and does not claim superiority of any commercial product or service
- Optometric Education Consultants Scottsdale, AZ, Orlando, FL, Mackinac Island, MI,
 Nashville, TN, and Quebec City, Canada Owner

Resource: OCT Community for OCT and OCT-A


OCT CONNECT


Post your questions & cases so we can #OCTConnect!




Join this group to become part of our OCT Connect Family!


Book Resources





Optical Coherence Tomography Course Design





OCT and OCT Angiography

Both are Becoming Equally Important in Diagnosis, Management, and Treatment

Optical Coherence Tomography


- GAY OCT is an optical signal acquisition and processing method
- & Time domain OCT
 - * 15-16 microns of resolution
 - * Stratus (Zeiss)
- & Spectral domain (SD-OCT) or Fourier domain OCT
 - **★** Spatially encoded frequency domain OCT (SEFD-OCT)
 - **★** 5-6 microns of resolution
 - ☐ Able to see photoreceptor morphology (inner/outer segments)
 - * 50 times faster than time domain
- Swept source OCT
 - * Time encoded frequency domain OCT
 - * 1 micron of resolution
- & Future of OCT- intraoperative imaging, blood flow and oxygenation measurements
- A May have the possibility to assess retinal pathology like a pathologist

OCT Angiography: the Next Chapter in Posterior Imaging


- A lmages retinal microvasculature without dye injection
- Displays structure and function from a single imaging system



2006: Spectral Domain OCT



2014: OCTA




2002: Time Domain OCT


Where is the macula?


How large is the macula?



4 Basic Categories: Diseases of the....







ILM: Inner limiting membrane
IPL: Inner plexiform layer
INL: Inner nuclear layer
OPL: Outer plexiform layer
ONL: Outer nuclear layer

ELM: External limiting membrane
IS/OS: Junction of inner and outer
photoreceptor segments

OPR: Outer segment PR/RPE complex

NFL: Nerve fiber layer GCL: Ganglion cell layer

RPE: Retinal pigment epithelium

+ Bruch's Membrane

Thank You- Jian Zhou, MD



OCT Diagram of retina (choroid), and enhanced vitreous, marked by myself. Ratio in 9:20 in case needed for phone wallpaper.

Abbreviation dictionary as below:

NFL= nerve fiber layer

GCL= ganglion cell layer

IPL= inner plexiform layer

INL= inner nuclear layer

OPL= outer plexiform layer

ONL= outer nuclear layer

ELM= external limiting membrane

OS= outer segment line

COST= cone outer segment tip

RPE= retinal pigment epithelium

BRM= Bruch's membrane


SCP= superficial capillary plexus

ICP= intermediate capillary plexus


DCP= deep capillary plexus


Author: Jian Zhou, MD. (Toward Pi)


#OCT #SSOCT #Bscan



Thank You- Jian Zhou, MD










Normal Retinal Vasculature



Superficial Capillary Plexus

 $3\mu m$ Below ILM ightarrow 15 μm Below IPL

Deep Capillary Plexus

15 μ m Below ILM ightarrow 70 μ m Below IPL


Outer Retina


70 μ m Below IPL \rightarrow 30 μ m Below RPE Reference

Choriocapillaris


30 μm Below RPE Reference \rightarrow 60 μm Below RPE Reference

Review of Normal 25 year old man







Review of Normal 60 year old man



60 Year Old Montage OU








Learn to predict visual acuities

OCT Angiography A New Approach to Protecting Vision

- Non-invasive visualization of individual layers of retinal vasculature
- ▶ Pathology not obscured by fluorescein staining or pooling
- Image acquisition requires less time than a dye-based procedure
- ▶ Reduced patient burden allows more frequent imaging to better follow disease progression and treatment response







FA of CNV

OCTA of CNV

Enface OCT-A Slabs Based on Retinal Anatomy



Normal Retinal Vasculature



Superficial Capillary Plexus

 $3\mu m$ Below ILM ightarrow 15 μm Below IPL

Deep Capillary Plexus


15 μ m Below ILM ightarrow 70 μ m Below IPL

Outer Retina

70 μ m Below IPL \rightarrow 30 μ m Below RPE Reference

Choriocapillaris

30 μm Below RPE Reference \rightarrow 60 μm Below RPE Reference



Identify Early Vascular Changes in Diabetic Eyes

Patients with DM have a larger FAZ than healthy eyes.3


Diabetic Eye
FAZ Area: 0.443mm²

FAZ (peor): 0.433, PEIMI (peor): 2.633, (peor): 0.472, PEIMI (peor): 1.006, (peor): 0.472, PEIMI (peor): 1.006, (peor): 1.0

3. Di, G., Weihong, Y., Xiao, Z. et al. Graefes Arch Clin Exp Ophthalmology (2016) 254: 873. https://doi.org/10.1007/s00417-015-3143-7 Images courtesy of Julie Rodman, OD, FAAO


Assess Disease Progression with Multiscan View

Vessel Density Decreases Significantly with Disease Severity⁴





4. Nesper PL, Roberts PK, Onishi AC, et al. Quantifying Microvascular Abnormalities With Increasing Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography. Investigative Ophthalmology & Visual Science. 2017;58(6):BIO307-BIO315. doi:10.1167/iovs.17-21787.

Comprehensive Eye Exam - Healthy





Patient 1 with Diabetes







Patient 2 with Diabetes








Patient 3 with Diabetes



Patient 3 with Diabetes



58-year-old man with diabetes

ANew patient to the practice

⇔BS: unsure, last HbA1c unsure

ADM meds: metformin, glyburide, Invokana


€√Vision 20/20


Anterior segment: normal

Widefield Imaging










FAZ Damage — This is DR Time to get to know your BS and HBA1c



& BS: 134 this AM, last HbA1c 8.0


△ DM meds: Novolog and Amaryl


€√Vision 20/20


Anterior segment: normal


Widefield Imaging






























OCT and OCT-A

- Certainly useful, beneficial, essential, and important in following the patient with diabetes



Optometrists and All Eye Care Professionals Responsibility

- Rethink our responsibility related AMD diagnosis and management
- & Commit to that we will do better in
 - **★** Early detection
 - * Treatment
- Ar Know, execute, and employ current clinically appropriate Practice Guidelines
 - **★** Those that preserve vision
 - * Don't wait until vision has been lost
- Closely monitor and treat the early detected disease
 - * If progresses to advanced AMD, better opportunity to save vision

Instruments for AMD – fragmented care


```
& Slit lamp/DFE
```

- & Camera
- GOCT
- **G**→OCT Angiography
- **PHP**
- & Genetic testing

Beckmann Committee Classification of AMD


- Based on presence of lesions within 2 DD of fovea in either eye
 - * No AMD
 - □ None or few small drusen, < 63 microns
 - No AMD pigmentary abnormalities
 - **★ Early AMD**
 - ☐ Medium drusen, > 63 <125 microns
 - No AMD pigmentary changes
 - * Intermediate AMD
 - 1 large drusen, > 125 microns
 - Any AMD pigmentary changes
 - * Advanced AMD
 - Any geographic atrophy

AMD is a Disease Process that Starts Below the Surface







April 27, 2021 – January 26, 2022 (9 months)



Measure the Drusen with Your OCT



Measure the Drusen with Your OCT






OCT in AMD

- ANeed spectral domain to follow intermediate or worse AMD
- Able to identify OCT predictors of progression
- Especially in identifying OCT predictors of progression
 - **★** Hyper-reflective foci
 - **★** Reticular pseudodrusen
 - * Nascent geographic atrophy
 - **★** Sub-RPE hyper-reflective columns
 - **★** Drusen substructures
 - **★** Drusen load and regression

Hypo versus Hyper Reflectance



Can We Learn From These Pictures?




Can We Learn From These Pictures?







Hypo versus Hyper Reflectance




Case 1 - OCT Predictors of Progression




Case 1 - OCT Predictors of Progression




Case 1 - OCT Predictors of Progression




Case 2 - OCT Predictors of Progression




Case 2 - OCT Predictors of Progression




Case 2 - OCT Predictors of Progression




Case 3 - OCT Predictors of Progression




Case 4 - OCT Predictors of Progression




Case 5 - OCT Predictors of Progression



Case 5 - OCT Predictors of Progression




Case 5 - OCT Predictors of Progression




OCT Angiography in AMD Structure Test

- Able to identify occult or classic CNV before they leak
- A Non-invasive technique
- Subclinical CNV or "Occult non-exudative CNV"
 - * Risk of exudation at 12 months is 15.2 times greater compared to eyes without subclinical CNV

Type 1 "Occult" CNV






- ▶ New vessels develop in the choroid
- ▶ New vessels located below RPE and above Bruch's membrane

Type 1 "Occult" CNV

A New vessels develop in the choroid


ABOVE Bruch's membrane



CNV?





72 y/o Hispanic male 20/30 History of "Dry AMD"






Multimodal imaging and OCTA










Vascularized Non-vascularized


And the not so obvious ones...





Type 2 "Classic" CNV








- A New vessels develop in choroid
- A New vessels located above the RPE and above Bruch's membrane

Type 2 "Classic" CNV


- A New vessels develop in choroid
- AND New vessels located ABOVE the RPE and ABOVE Bruch's membrane








Why I Love to Teach



Retinal Angiomatous Proliferation



Stage 1

Intra-retinal proliferation

*Hemes *Edema

*Exudate

Stage 2


Neovascularization penetrates the sub-retinal space


*Neurosensory detachment *Serous PED

Stage 3


Neovascularization penetrates the RPE space

*Vascularized PED; CNVM





Inspect the SD-OCT carefully!!



VA 20/40


HYPER-REFLECTIVE lesion above pigment epithelial detachment


Intraretinal cysts

Serous pigment epithelial detachment/ neurosensory detachment


Stage 2








Stage 3





http://imagebank.asrs.org/file/26943/retinal-angiomatous-proliferation


https://www-ncbi-nlm-nih-gov.ezproxylocal.library.nova.edu/pubmed/29019795

What about the OCTA?

OCT angiography demonstrates retinal angiomatous proliferation and chorioretinal anastomosis of type 3 neovascularization


Reema Bansal · Varshitha Hemanth · Samyak Mulkutkar · Ramandeep Singh Vishali Gupta · Mangat R. Dogra · Amod Gupta

Type 3 CNV: Intraretinal Anastomosis: THROUGH RPE





Inner retina (SCP+DCP) to Outer retina (Avascular/choriocapillaris)

OCT Angiography Evaluation AMD



OCT Angiography Evaluation AMD After and Before Bevacizumab (Avastin)






OCT Angiography


Subclinical CNV or "Occult non-exudative CNV"

Risk of exudation at 12 months is 15.2 times greater compared to eyes without subclinical CNV

Occult Non-Exudative CNV Patient A




Occult Non-Exudative CNV Patient A



HD Angio Retina Right / OD Scan Quality 3/10 6.00 x 5.00 Scan Size (mm) Export Angio 9.0 En Face | Thickness | RPE Elevation | Color Overlay | 3D Display OverVue QuickVue □ Edit Bnd Restore Settings Play En Face Slab C Superficial Show Bnd C Deep C Outer Retina ☐ No MCT © Choriocapillaris Color C Custom Show Lines Upper - BRM Offset(um) Lower - BRM Offset(um) ✓ Auto Zoom 🖭 🔾

Occult Non-Exudative CNV Patient A

Which is More Suspicious?



Treatments for AMD

- Early detection and meaningful treatments with significant value, do not cure, but have been shown to slow or halt progression. Not limited to early stages but all stages of AMD
 - **★** Prescribe smoking cessation programs
 - Smoking and AMD
 - Depletes serum antioxidants
 - Decreases pigmentary density
 - Increases risk to advanced AMD
 - * Lifestyle changes
 - 🖺 Diet
 - **Exercise**
 - * Systemic disease management
 - Tardiovascular disease, DM, obesity, high cholesterol

A Nutritional supplements


- * Sub-clinical/sub-structural or early disease
 - Controversy flourishes
 - No definitive guideline exists
 - Despite consensus evidence suggests using supplements
- * Intermediate advance disease
 - ☼ No controversy on advocating for supplements
- * AREDS 1
 - Contains Beta-carotene and no lutein or zeaxanthin, no longer recommended
 - Investigated early AMD, no statistically significant benefit
- * AREDS 2
 - ® Recommended for intermediate and advanced AMD, study protocol
- * The Practical Guide for the Treatment of AMD 3 primary options
 - Macular pigment supplement
 - Carotenoids: lutein, zeaxanthin, meso-zeaxanthin
 - ☐ Carotenoids, antioxidants, zinc, and vitamins C & E
 - AREDS 2
 - © Carotenoid macular supplement in subclinical and early AMD. Carotenoid and antioxidant is intermediate and AMD that is progressing


Treatment for AMD

Treatment for AMD

- Retinal light protection
 - **★** Sun exposure
- &Closer follow up
 - * 12 months is currently accepted as being too long to defect progression
 - * 6 months or sooner based on risk of CNV
- & Low vision and rehabilitation consultation

Macular Pigment









Macular Pigment

Imaging lutein and zeaxanthin in the human retina with confocal resonance Raman microscopy


Binxing Li^a, Evan W. George^a, Gregory T. Rognon^a, Aruna Gorusupudi^a, Arunkumar Ranganathan^a, Fu-Yen Chang^a, Linjia Shi^a, Jeanne M. Frederick^a, and Paul S. Bernstein^{a,1}

^aDepartment of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132







Macular Pigment and the Retina











Raman Intensity map of total carotenoids in a human retinal section. (Top) A



Macular Pigment



Oxidative Medicine and Cellular Longevity

Oxid Med Cell Longev. 2019; 2019: 9783429.

Oxid Med Cell Lor

Oxid Med Cell Longev

Published online 2019 Feb 12. doi: 10.1155/2019/9783429

PMCID: PMC6390265

PMID: 30891116

Health Benefits of Polyphenols and Carotenoids in Age-Related Eye Diseases

Simona Bungau, ¹ Mohamed M. Abdel-Daim, [®] ² · ³ Delia Mirela Tit, ¹ Esraa Ghanem, [®] ⁴ Shimpei Sato, ³ Maiko Maruyama-Inoue, ³ Shin Yamane, ³ and Kazuaki Kadonosono ³

▶ Author information ▶ Article notes ▶ Copyright and License information Disclaimer

This article has been cited by other articles in PMC.

Abstract Go to: ♥

Oxidative stress and inflammation play a critical role in the initiation and progression of age-related ocular abnormalities as cataract, glaucoma, diabetic retinopathy, and macular degeneration. Therefore, phytochemicals with proven antioxidant and anti-inflammatory activities, such as carotenoids and polyphenols, could be of benefit in these diseases. We searched PubMed and Web of Science databases for original studies investigating the benefits of different carotenoids and polyphenols in age-related ophthalmic diseases. Our results showed that several polyphenols (such as anthocyanins, Ginkgo biloba, quercetin, and resveratrol) and carotenoids (such as lutein, zeaxanthin, and mezoxanthin) have shown significant preventive and therapeutic benefits against the aforementioned conditions. The involved mechanisms in these findings include mitigating the production of reactive oxygen species, inhibiting the tumor necrosis factor-α and vascular endothelial growth factor pathways, suppressing p53-dependent apoptosis, and suppressing the production of inflammatory markers, such as interleukin- (IL-) 8, IL-6, IL-1a, and endothelial leucocyte adhesion molecule-1. Consumption of products containing these phytochemicals may be protective against these diseases; however, adequate human data are lacking. This review discusses the role and mechanisms of polyphenols and carotenoids and their possible synergistic effects on the prevention and treatment of age-related eye diseases that are induced or augmented by oxidative stress and inflammation.

Carotenoids and Polyphenols

ww.oncotarget.com

Oncotarget, 2018, Vol. 9, (No. 24), pp: 17181-17198

Revie

Oncotarget

Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging

Carolina Simioni¹, Giorgio Zauli¹, Alberto M. Martelli², Marco Vitale^{3,4}, Gianni Sacchetti⁵, Arianna Gonelli¹ and Luca M. Neri¹

Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

Correspondence to: Luca M. Neri, email: Juca neri@unife.it

Keywords: exercise training: nutroceuticals: flavonoids intake; aging: antioxidant supplementation

Received: January 26, 2018 Accepted: March 08, 2018 Published: March 30, 201

Copyright: Simioni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Resveratrol can be implied in anti-aging actions by influencing the mitochondrial environment and metabolic diseases, by regulating the levels of some inflammatory mediators and cytokines and by modulating lipolysis [125, 152, 153]. Mitochondrial dysfunction has been proved to be associated with aging and disease development [154], and it was seen

Furthermore, resveratrol maintains the vascular fitness through its antioxidant and anticoagulant activities, and on the other hand is relevant in blocking the formation of new blood vessels, in inhibiting the VEGF release and attenuating Hypoxia-Inducible Factor (HIF-1α) in different tumor cells [163].

It is reported that also auroumin neggogge anti-

ASSESSMENT OF CAROTENOIDS

Impact of Carotenoid Assessment

Because carotenoids appear to play a key role in retinal diseases, intensive research has resulted in a variety of innovative carotenoid assessment techniques. The breadth of possibilities for assessing retinal carotenoids is often confusing because methodologies, units of measurement, and the presentation of results vary widely. Accurate readings of carotenoid status are important in order to correctly advise individuals with regards to supplementation. Furthermore, in diseases such as macular telangiectasia type 2 (MacTel), the assessment of carotenoids may be crucial to the diagnosis, as reduced MP levels as well as abnormal distributions are among the first signs of the disease. Therefore, the measurement of carotenoids can impact clinical practice, and the evaluation of MP may eventually become an integral part of comprehensive ophthalmological care. The following sections describe and aim to give an organized overview of different MP assessment techniques.

A large variety of methods are used to assess carotenoid status in humans, most of which are focused on the eye, but carotenoids can also be measured in tissue outside of the eye, such as the skin, blood, and the brain. Measurements of ocular carotenoids can be distinguished between subjective (psychophysical) and objective (optical) methods used to assess the amount of MP. In subjective methods, a direct answer from the patient is required, whereas objective measurement methods typically require just enough cooperation to generate an image (73).

Annu. Rev. Nutr. 2019 39:95-120. Downloaded from www.annualrevie ccess provided by Dartmouth College - Main Library on 01/12/21. For pers

89

²Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

³Department of Medicine and Surgery, University of Parma, Parma, Italy

⁴CoreLab, Azienda Ospedallero-Universitaria di Parma, Parma, Italy

⁵Department of Life Sciences and Biotechnology, Pharmaceutical Biology Laboratory, University of Ferrara, Ferrara, Italy

Measuring Macular Pigment

- Retina macula biopsy
- & Clinical Imaging
 - * Subjective
 - **TeaVision MPSII**
 - ☐ Guardion Mapcat SF
 - * Clinical
 - **ZeaVision MPR**
 - ☐ Zeiss Visucam 200
 - ☐ Spectralis HRA+OCT
 - □ Spectralis MPOV


















Thank you! Dr. Chris Putnam

Measuring Macular Pigment

& Biophotonic Scanner

- **★** Measures carotenoids
- *Based on an optical method known as Resonant Raman Spectroscopy (RSS)
 - Used for many years in research laboratories
- **★** Skin RRS measurements
 - Noninvasive
 - Objective
 - Reliable methods to assess carotenoid levels
 - Ocular
 - Systemic



ARVO STUDY

Interrelationships between Macula, Skin and Serum Carotenoids- Paul Bernstein, Werner Gellerman et al ARVO May 2016

Conclusions:

"Our results emphasize the importance of measuring the total amount of carotenoids in the macula region using an objective image based modality such as AFI w Spectralis rather than subjective MPOD."

Skin resonance Raman Spectroscopy of skir carotenoids is a reasonable biomarker of macula carotenoid status. and correlates better than than subjective MPOD tests.



The objective hand scanner is better than the subjective Macuscope, QuantifEYE, and Densitometer for estimating macula pigment.

Carotenoid Levels






Quick Test (approx. 30 sec)

Portable

Cost Effective

Remeasure in 60 days

Reassurance to you and patient



53-year-old man

- - * Dad with 43 injections for AMD
- & Pre-diabetic with borderline HbA1c
- ⇔Vision 20/20 OU
- **⇔**OCT normal

CONGRATULATIONS ON TAKING THE FIRST STEPS TOWARDS OPTIMIZING YOUR SCS

Dea

Recently, on 12/15/2020, you met with me and I scanned the palm of your hand with the BioPhotonic Scanner. Your scan returned a Skin Carotenoid Score (SCS) of 26000.

This score represents the current carotenoid level of your skin. The higher the score, the more carotenoids your body is receiving.



26000

Ingredients

Ingredients	Amount	% Daily Value
Serving Size: 1 Packet		
Vitamin A (83% as Beta Carotene (1875 mcg RAE) from Blakeslea trispora, and Vitamin A palmitate) (375 mcg RAE)	2250 mcg RAE	250%
Vitamin C (as Calcium Ascorbate)	200 mg	222%
Vitamin D (as Cholecalciferol)	5 mcg (200 IU)	25%
Vitamin E (as D-Alpha-Tocopheryl Acetate, D-Alpha Tocopherol, Tocotrienols)	50.3 mg	335%
Vitamin K (as Phytonadione)	20 mcg	17%
Thiamin (as Thiamine Mononitrate)	3.75 mg	313%
Riboflavin (as Riboflavin)	4.25 mg	327%
Niacin (as Niacinamide)	17.5 mg NE	109%
Vitamin B6 (as Pyridoxine Hydrochloride)	5 mg	294%
Folate	500 mcg DFE (300 mcg folic acid)	125%
Vitamin B12 (as Cyanocobalamin)	15 mcg	625%
Biotin (as Biotin)	75 mcg	250%
Pantothenic Acid (as D-Calcium Pantothenate)	15 mg	300%
Calcium (as Calcium Carbonate, Di-Calcium Malate, Calcium Ascorbate)	250 mg	19%

Calcium (as Calcium Carbonate, Di-Calcium Malate, Calcium Ascorbate)	250 mg	19%
lodine (as Potassium Iodide)	50 mcg	33%
Magnesium (as Magnesium Glycinate, Magnesium Oxide)	125 mg	30%
Zinc (as Zinc Bisglycinate)	7.5 mg	68%
Selenium (as L-Selenomethionine, Sodium Selenite)	70 mcg	127%
Copper (as Copper Bisglycinate)	0.5 mg	56%
Manganese (as Manganese Bisglycinate)	1 mg	43%
Chromium (as Chromium Nicotinate Glycinate)	100mcg	286%
Molybdenum (as Molybdenum Bisglycinate)	37.5 mcg	83%
Polyphenol and Flavonoid Blend	97.5 mg	*
Catechins (from <i>Camellia sinensis</i> Leaf Extract)	(45 mg)	*
Quercetin	(25 mg)	*
Grape Seed Extract (min. 95% Polyphenols)	(12.5 mg)	*
Citrus Bioflavonoids (from Citrus Fruits)	12.5 mg)	*
Resveratrol (from <i>Polygonum cuspidatum</i> root extract)	(2.5 mg)	*
Mixed Tovopherols (Gamma, Delta & Beta Tocopherols)	53 mg	*
Alpha-Lipoic Acid	15 mg	*
Inositol (as Inositol)	5 mg	*
Carotenoid Blend	3.5 mg	*
Lycopene (as Lycopene)	(2.5 mg)	*
Lutein (from Marigold Flower Extract)	(1 mg)	*
Boron (as Boron Citrate)	1.5 mg	*
Vanadium (as Vanadyl Sulfate)	10 mcg	*

OTHER INGREDIENTS: Gelatin, Microcrystalline Cellulose, Crosmarmellose Sodium, Stearic Acid, Magnesium Stearate, Silicon Dioxide, Titanium Dioxide.

CONTAINS: Fish (Cod, Pollack, Haddock, Hake, Cusk, Redfish, Sole, Flounder).

SUPPLEMENT FACTS

Serving Size 2 Softgels Servings Per Container 6 Amount Per Serving % D				
dente i principale de la Contraction de la Pro-	465	24 104		
Total Calories Total Fat Saturated Fat <i>Trans</i> Fat	15 1 g 0 g 0 g	196° 096°		
Vitamin D3 (as cholecalciferol) Vitamin K2 (as menaquinone-7)	12.5 mcg (500 IU) 20 mcg	63% 17%		
Ultra-pure fish oil concentrate:	1055 mg	- 2		
EPA (Eicosapentaenoic acid)	300 mg	**		
DHA (Docosahexaenoic acid)	200 mg	**		
Citrus Bioflavonoids (including hesperidin and naringin)	100 mg	**		
Purple corn (Zea mays L.) cob extract including anthocyanins	66.67 mg	**		
Alpha Lipoic Acid	50 mg	**		
Quercetin (from Dimorphandra moilis fruit extract)	37.5 mg	**		
D-Limonene (from Citrus sinensis peel)	25 mg	22		
Rosemary (Rosmarinus officinalis L.) leaf extract including carnosic acid	18.75 mg	**		
Resveratrol (from Polygonum cuspidatum root)	15 mg	**		
Coenzyme Q10	15 mg	**		
Lycopene	2.5 mg			
Lutein (from manigold flower (Targetes erectal)	2 mg	**		
Astaxanthin (from Haematococcus pluvialis algae)	0.5 mg	***		

OTHER INGREDIENTS: Gelatin, Glycerin, Beeswax, Sunflower Lecithin, Vanillin.

CONTAINS: Fish (anchovies, sardines, mackerel).

53-year-old man

CONGRATULATIONS ON TAKING THE FIRST STEPS TOWARDS OPTIMIZING YOUR SCS

Door

Recently, on 12/27/2020, you met with me and I scanned the palm of your hand with the BioPhotonic Scanner. Your scan returned a Skin Carotenoid Score (SCS) of 33000.

This score represents the current carotenoid level of your skin. The higher the score, the more carotenoids your body is receiving.



33000

CONGRATULATIONS ON TAKING THE FIRST STEPS TOWARDS OPTIMIZING YOUR SCS


Dear

Recently, on 01/23/2021, you met with me and I scanned the palm of your hand with the BioPhotonic Scanner. Your scan returned a Skin Carotenoid Score (SCS) of 47000.


This score represents the current carotenoid level of your skin. The higher the score, the more carotenoids your body is receiving.



47000



April 27, 2021 – January 26, 2022 (9 months)





Questions? Thank You!

OCT and OCT Angiography Something Old and Something New Retina Pearls

Greg Caldwell, OD, FAAO

Nashville – Music City Fall Classic 2022 Optometric Education Consultants

Saturday, October 22, 2022

